Nutra Pharma Corp under the ticker symbol NPHC. Here is some more information that we have about Nutra Pharma Corp

Get our alerts and future stock picks in your email inbox

Nutra Pharma Corp
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma Corporation, through its subsidiary, ReceptoPharm, engages in the development of Cobroxin, Nyloxin OTC, and Nyloxin Rx for the treatment of moderate to severe chronic pain; RPI-78M for the treatment of neurological diseases, including Multiple Sclerosis, Adrenomyeloneuropathy, Amyotrophic Lateral Sclerosis, and Myasthenia Gravis; and RPI-MN for the treatment of viral diseases comprising HIV/AIDS and herpes. ReceptoPharm also provides contract research services through its ISO class 5 and good manufacturing practice certified facilities to third-party biotechnology and pharmaceutical companies. In addition, the company, through its other subsidiary, Designer Diagnostics, involves in the research, development, and sale of diagnostic test kits used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria. Nutra Pharma Corporation continues to identify intellectual property and companies in the biotechnology arena. The company was founded in 2000 and is based in Coral Springs, Florida.
5 Employees
Last Reported Date: 04/13/15
Founded in 2000
Last $0.20 USD
Change Today +0.0199 / 11.06%
Volume 45.5K
As of 3:50 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

nutra pharma corp (NPHC) Snapshot

Open
$0.15
Previous Close
$0.18
Day High
$0.21
Day Low
$0.15
52 Week High
08/6/14 - $0.43
52 Week Low
05/19/15 - $0.05
Market Cap
7.9M
Average Volume 10 Days
154.3K
EPS TTM
$-0.43
Shares Outstanding
39.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Request Investor Kit
NPHC:US Advanced Stock Chart

Related News

No related news articles were found.

nutra pharma corp (NPHC) Related News

No Related News Found

nutra pharma corp (NPHC) Key Developments

Nutra Pharma Corporation Enters into Facility and Personnel Sharing Agreement with Nationwide Laboratory Services, Inc

Nutra Pharma Corporation announced that they have entered into a facility and personnel sharing agreement with Nationwide Laboratory Services, Inc.

Nutra Pharma Corporation announced delayed 10-Q filing

On 05/18/2015, Nutra Pharma Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Nutra Pharma Corporation will Change its Ticker to NPHC.D from NPHC

Effective May 18, 2015, Nutra Pharma Corporation will change its Pink Sheets LLC stock ticker symbol to NPHC.D from NPHC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NPHC:US $0.20 USD +0.0199

NPHC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €128.26 EUR +2.27
Biogen Inc $405.41 USD +1.47
Roche Holding AG SFr.266.30 CHF +4.30
 

Industry Analysis

NPHC

Industry Average

Valuation NPHC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Nutra Pharma Announces Manufacturing Release of Pet Pain-Away and Delivery of Initial Orders
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , announced today that they have received their first manufacturing run ...
  Read More...
Nutra Pharma Letter to Shareholders
[Marketwired] - Nutra Pharma Corporation , a biotechnology company that is developing treatments for Multiple Sclerosis , Human Immunodeficiency Virus , Adrenomyeloneuropathy and Pain, announced today that the Company's ...
  Read More...
NUTRA PHARMA CORP Financials
  Read More...
10-Q for Nutra Pharma Corp.
  Read More...
NUTRA PHARMA CORP Files SEC form 10-Q, Quarterly Report
  Read More...
Nutra Pharma Announces Laboratory Recertification and Manufacturing Updates
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing the recertification of their Plantation, Florida laboratory ...
  Read More...
Nutra Pharma Retains BUYINS.NET to Surveil Short Sellers and Market-Makers
[Marketwired] - Nutra Pharma Corp
  Read More...
Nutra Pharma Provides Nyloxin(R) Marketing Updates
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing updates to the marketing plan for their over-the-counter ...
  Read More...
NUTRA PHARMA CORP Files SEC form 10-Q/A, Quarterly Report
  Read More...
Nutra Pharma Announces Engagement of Investment Banking Firm Pickwick Capital Partners to Provide Strategic Advisory Services
[Marketwired] - Nutra Pharma Corporation , a biotechnology company marketing Nyloxin® and Pet Pain-Away in the over-the-counter pain management market, and which is also developing treatments for Multiple Sclerosis , ...
  Read More...
Nutra Pharma Announces Nyloxin Television Commercial Rollout
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin.com, a company that has the exclusive rights ...
  Read More...
Nutra Pharma Announces Completion of Commercials by MyNyloxin.com
[Marketwired] - Nutra Pharma Corp. , a biotechnology company that is developing treatments for Adrenomyeloneuropathy , HIV and Multiple Sclerosis , is announcing that MyNyloxin.com, a new company that has the exclusive ...
  Read More...
Nutra Pharma Announces Expansion and Upgrades for Nyloxin(R) Production
[Marketwired] - Nutra Pharma Corporation , a biotechnology company marketing Nyloxin® and Pet Pain-Away in the over-the-counter pain management market, and which is also developing treatments for Multiple Sclerosis , ...
  Read More...
Nutra Pharma Announces Collaboration With Nationwide Laboratories
[Marketwired] - Nutra Pharma Corporation , a biotechnology company marketing Nyloxin and Pet Pain-Away in the over-the-counter pain management market, and which is also developing treatments for Multiple Sclerosis , Human ...
  Read More...
Nutra Pharma Announces Orphan Drug Applications for RPI-78M
[Marketwired] - Nutra Pharma Corporation , a biotechnology company that is developing treatments for Multiple Sclerosis , Human Immunodeficiency Virus , Adrenomyeloneuropathy and Pain, announced today that they have engaged ...
  Read More...
Nutra Pharma Announces Nyloxin(R) Distribution Plans for Canada
[Marketwired] - Nutra Pharma Corporation , a biotechnology company that is developing treatments for Multiple Sclerosis , Human Immunodeficiency Virus , Adrenomyeloneuropathy and Pain, announced today that they have engaged ...
  Read More...
Nutra Pharma Announces Nyloxin(R) Acceptance by Chinese Medical Authority - CPAM
[Marketwired] - Nutra Pharma Corporation , a biotechnology company that is developing treatments for Multiple Sclerosis , Human Immunodeficiency Virus , Adrenomyeloneuropathy and Pain, announced today that they have received ...
  Read More...
NUTRA PHARMA CORP Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Articles of
  Read More...
10-K for Nutra Pharma Corp.
  Read More...
Nutra Pharma Announces Nyloxin(R) Distribution Plans for China
[Marketwired] - Nutra Pharma Corporation , a biotechnology company that is developing treatments for Multiple Sclerosis , Human Immunodeficiency Virus , Adrenomyeloneuropathy and Pain, announced today that they have engaged ...
  Read More...